FlowSense™ Noninvasive Thermal Sensor Improves Shunt Management in Patients

US-based Rhaeos Inc discovered FlowSense™ Noninvasive Thermal Sensor designed to enhance shunt management in patients with hydrocephalus.

FlowSense™ Noninvasive Thermal Sensor is developed to monitor ventricular shunt functioning in patients with excess cerebrospinal fluid caused by hydrocephalus.

Conventionally, ventricular shunt failure is diagnosed by computed tomography (CT) and magnetic resonance imaging (MRI) which is more expensive thus exposing people to much radiation. FlowSense™ is thus introduced to overcome these challenges. It can be placed bedside on a patient's neck, overlaying the shunt, to detect the flow of cerebrospinal fluid. The new sensor can show immediate results by detecting shunt functionality in 5 minutes and wirelessly transmit to a mobile app to improve clinical decision making.

Over 1 million American’s especially children are affected with Hydrocephalus. Unfortunately, 50 per cent of neurosurgically implanted shunts fail within first two years of shunt placement which is considered to be the treatment to manage this disease. Shunt failure in patients with hydrocephalus occurring at any time has become a serious life threating issue. Lack of diagnostic tools is making it different to determine the presence of shunt failure of patients in today’s world. FlowSense™ can now easily detect cerebrospinal fluid shunt flow eliminating delays caused by diagnostic testing and providing a treatment option for patients.

FlowSense™ has been approved under FDA's regulations.